Researchers from University of Illinois Report Recent Findings in Gene Therapy (The Impact of Capping Health System Cost Savings On the Projected Cost-effectiveness of Etranacogene Dezaparvovec Compared With Factor Ix Prophylaxis for the...).

A recent study conducted by researchers from the University of Illinois explores the cost-effectiveness of Etranacogene Dezaparvovec, a gene therapy for hemophilia B. The study utilizes the Institute for Clinical and Economic Review's framework for single and short-term therapies (SSTs) to assess the long-term benefits of Etranacogene Dezaparvovec compared to current factor IX prophylaxis. The researchers found that while Etranacogene Dezaparvovec offers substantial cost savings in the standard full cost-offset analysis, the cost-effectiveness is significantly reduced when considering the ICER SST framework, particularly the $150,000 annual cap scenario. The study suggests that frameworks like ICER SST can help improve efficiency in resource allocation and balance incentives for innovation with economic sustainability in managed care systems. [Extracted from the article]